drugset / Trial / NCT03188185

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

NCT03188185

Phase 3 Completed 278 enrolled Alkermes, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the efficacy, safety, and tolerability of adjunctive ALKS 5461 in adults who have treatment refractory MDD.

Timeline

Start
2017-06-12
Primary completion
2020-02-26
Completion
2020-03-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified Other
Subject Samidorphan Small molecule Other